Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 5:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,659 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia; Psychosis Clear all
Terminated Phase 1Phase 2 Interventional Results available

A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis

NCT00591318
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizoaffective Disorder
Interventions
ceftriaxone, Normal Saline
Drug
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 16, 2026, 5:35 AM EDT
Completed Phase 2 Interventional

Cognitive Training to Improve Work Outcomes in Severe Mental Illness

NCT00895258
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Depression
Interventions
Individual placement and support plus cognitive training (IPS-CT), Individual placement and support plus enhanced support (IPS-ES)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 16, 2026, 5:35 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

NCT01678755
View directory record Official record
Conditions
Schizophrenia
Interventions
ABT-126, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
20 Years to 55 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
20
States / cities
Chino, California • Garden Grove, California • National City, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Oct 16, 2026, 5:35 AM EDT
Withdrawn No phase listed Observational

Sleep Quality, Cognitive Performance, and Computerized Cognitive Training

NCT06328140
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder, Psychosis
Interventions
Lurasidone, FDA Approved antidepressant treatment
Drug
Lead sponsor
George West Mental Health Foundation d/b/a Skyland Trail
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 16, 2026, 5:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cigarette Smoking in Smokers With and Without Schizophrenia

NCT04001114
View directory record Official record
Conditions
Tobacco Dependence, Schizophrenia
Interventions
Sampling Research Cigarettes
Combination Product
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 16, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia

NCT01003379
View directory record Official record
Conditions
Cognitive Dysfunction, Schizophrenia
Interventions
TC-5619, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
7
States / cities
National City, California • Torrance, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 16, 2026, 5:35 AM EDT
Completed Not applicable Interventional Results available

Improving Accessibility and Personalization of CR for Schizophrenia

NCT03576976
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cognitive Remediation
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Brooklyn, New York • New York, New York • Orangeburg, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 16, 2026, 5:35 AM EDT
Completed Phase 4 Interventional

Treatment of Behavioral Symptoms in Alzheimer's Disease

NCT00009217
View directory record Official record
Conditions
Alzheimer's Disease, Psychosis, Agitation
Interventions
Haloperidol-Haloperidol, Haloperidol-Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
50 Years to 95 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Oct 16, 2026, 5:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults

NCT01429740
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-05180999, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 16, 2026, 5:35 AM EDT
Completed Not applicable Interventional

Adaptation of Cognitive Enhancement Therapy for Persons at Clinical High Risk for Psychosis

NCT02459210
View directory record Official record
Conditions
Psychosis
Interventions
CLUES, therapy and computer games
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
16 Years to 25 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 16, 2026, 5:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills

NCT00223418
View directory record Official record
Conditions
Schizophenia Disorder, Schizoaffective Disorder
Interventions
aripiprazole
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 52 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Oct 16, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Results available

A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia

NCT02164981
View directory record Official record
Conditions
Schizophrenia
Interventions
sodium nitroprusside, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Glen Oaks, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 16, 2026, 5:35 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)

NCT02970292
View directory record Official record
Conditions
Schizophrenia
Interventions
Pimavanserin, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
33
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 16, 2026, 5:35 AM EDT
Completed Phase 4 Interventional

Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder

NCT00090012
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Olanzapine, Quetiapine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
25
States / cities
Garden Grove, California • La Mesa, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 16, 2026, 5:35 AM EDT
Completed Phase 1 Interventional

18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia

NCT06880328
View directory record Official record
Conditions
Schizophrenia
Interventions
Ralmitaront, Radiolabeled PET tracer [18F]-DOPA, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Glendale, California • Torrance, California • Gaithersburg, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 16, 2026, 5:35 AM EDT
Not listed Not applicable Interventional

Quetiapine Decreases Smoking in Patients With Chronic Schizophrenia

NCT00231101
View directory record Official record
Conditions
Smoking Behavior in Schizophrenia
Interventions
Quetiapine
Drug
Lead sponsor
Arthur P. Noyes Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 17, 2006 · Synced Oct 16, 2026, 5:35 AM EDT
Completed Phase 4 Interventional

Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia

NCT00034801
View directory record Official record
Conditions
Depression, Schizophrenia, Schizoaffective Disorder
Interventions
olanzapine, ziprasidone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
30
States / cities
Tuscaloosa, Alabama • Little Rock, Arkansas • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 16, 2026, 5:35 AM EDT
Terminated Not applicable Interventional Results available

Oxytocin Add on Study for Stable Schizophrenic Patients

NCT00506909
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
David Feifel
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 16, 2026, 5:35 AM EDT
Completed Not applicable Interventional

A Multi-Site Study of Strategies for Implementing Schizophrenia Guidelines

NCT00013000
View directory record Official record
Conditions
Schizophrenia
Interventions
Test strategy for implementation guideline
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
6
States / cities
Washington D.C., District of Columbia • New Orleans, Louisiana • Tuscaloosa, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 16, 2026, 5:35 AM EDT
Completed Not applicable Interventional

Generalization of Training in Schizophrenia

NCT00108199
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Problem-Solving Training, Work-Related Social Skills Training
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 16, 2026, 5:35 AM EDT
Recruiting Phase 4 Interventional

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

NCT05648591
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder
Interventions
Iloperidone
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
11
States / cities
Dothan, Alabama • Little Rock, Arkansas • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 16, 2026, 5:35 AM EDT
Completed Phase 1 Interventional

Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia

NCT03150771
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Little Rock, Arkansas • San Diego, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 16, 2026, 5:35 AM EDT
Completed Not applicable Interventional Results available

Benefits of Physical Exercise in Schizophrenia

NCT02716584
View directory record Official record
Conditions
Schizophrenia
Interventions
Physical exercise, Stretching exercise
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 16, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Results available

Effects of Pentazocine Versus Lorazepam on Manic Symptoms

NCT00431184
View directory record Official record
Conditions
Bipolar Disorder, Schizoaffective Disorder, Manic Disorder, Mania, Manic State
Interventions
Pentazocine, Lorazepam
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 16, 2026, 5:35 AM EDT